-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ImmunoGen (NASDAQ:IMGN) Earns Overweight Rating From Analysts at Barclays
ImmunoGen (NASDAQ:IMGN) Earns Overweight Rating From Analysts at Barclays
Barclays began coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $8.00 price target on the biotechnology company's stock.
Separately, StockNews.com downgraded shares of ImmunoGen from a hold rating to a sell rating in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $9.80.
Get ImmunoGen alerts:ImmunoGen Stock Down 0.4 %
NASDAQ:IMGN opened at $5.44 on Friday. The company has a fifty day simple moving average of $5.40 and a two-hundred day simple moving average of $4.84. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -7.88 and a beta of 0.90. ImmunoGen has a 52 week low of $3.10 and a 52 week high of $7.77.
ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The business had revenue of $14.20 million during the quarter, compared to analyst estimates of $16.18 million. ImmunoGen had a negative return on equity of 67.02% and a negative net margin of 179.64%. The business's revenue was down 16.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.15) EPS. On average, analysts expect that ImmunoGen will post -0.89 EPS for the current year.Hedge Funds Weigh In On ImmunoGen
A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its stake in shares of ImmunoGen by 4.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotechnology company's stock worth $457,000 after purchasing an additional 2,406 shares in the last quarter. TFC Financial Management grew its stake in shares of ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 2,750 shares in the last quarter. Blair William & Co. IL grew its stake in shares of ImmunoGen by 0.5% during the first quarter. Blair William & Co. IL now owns 538,410 shares of the biotechnology company's stock worth $2,563,000 after purchasing an additional 2,925 shares in the last quarter. Kestra Advisory Services LLC grew its stake in shares of ImmunoGen by 14.6% during the first quarter. Kestra Advisory Services LLC now owns 23,468 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,985 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of ImmunoGen by 4.4% during the first quarter. Mackenzie Financial Corp now owns 80,816 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 3,370 shares in the last quarter. Institutional investors and hedge funds own 95.58% of the company's stock.
About ImmunoGen
(Get Rating)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Featured Articles
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
Barclays began coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $8.00 price target on the biotechnology company's stock.
据MarketBeat Ratings报道,巴克莱在周五向投资者发布的一份研究报告中开始对免疫系统(纳斯达克代码:IMGN-GET Rating)的股票进行报道。该经纪公司对这家生物技术公司的股票发布了增持评级和8.00美元的目标价。
Separately, StockNews.com downgraded shares of ImmunoGen from a hold rating to a sell rating in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $9.80.
另外,StockNews.com在8月1日星期一的一份研究报告中将ImmunoGen的股票评级从持有评级下调为卖出评级。一名分析师对该股的评级为卖出,两名分析师发布了持有评级,三名分析师对该股给予了买入评级。根据MarketBeat.com的数据,该股目前的普遍评级为持有,平均目标价为9.80美元。
ImmunoGen Stock Down 0.4 %
免疫基因公司股价下跌0.4%
NASDAQ:IMGN opened at $5.44 on Friday. The company has a fifty day simple moving average of $5.40 and a two-hundred day simple moving average of $4.84. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -7.88 and a beta of 0.90. ImmunoGen has a 52 week low of $3.10 and a 52 week high of $7.77.
纳斯达克:IMGN上周五开盘报5.44美元。该公司的50日简单移动均线切入位在5.40美元,200日简单移动均线切入位在4.84美元。该公司市值为12.亿美元,市盈率为-7.88倍,贝塔系数为0.90。ImmunoGen的52周低点为3.10美元,52周高位为7.77美元。
Hedge Funds Weigh In On ImmunoGen
对冲基金参与了免疫基因的研究
A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its stake in shares of ImmunoGen by 4.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotechnology company's stock worth $457,000 after purchasing an additional 2,406 shares in the last quarter. TFC Financial Management grew its stake in shares of ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 2,750 shares in the last quarter. Blair William & Co. IL grew its stake in shares of ImmunoGen by 0.5% during the first quarter. Blair William & Co. IL now owns 538,410 shares of the biotechnology company's stock worth $2,563,000 after purchasing an additional 2,925 shares in the last quarter. Kestra Advisory Services LLC grew its stake in shares of ImmunoGen by 14.6% during the first quarter. Kestra Advisory Services LLC now owns 23,468 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,985 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of ImmunoGen by 4.4% during the first quarter. Mackenzie Financial Corp now owns 80,816 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 3,370 shares in the last quarter. Institutional investors and hedge funds own 95.58% of the company's stock.
一些机构投资者和对冲基金最近调整了对该公司的持股。第四季度,法国巴黎银行套利公司持有的免疫系统股票增加了4.1%。法国巴黎银行套利公司现在持有这家生物技术公司61,561股股票,价值45.7万美元,上个季度又购买了2,406股。今年第一季度,TFC金融管理公司持有的免疫系统股票增加了18.1%。TFC金融管理公司现在持有这家生物技术公司17,950股股票,价值85,000美元,上个季度又购买了2,750股。在第一季度,Blair William&Co.IL增持了免疫基因公司的股份0.5%。Blair William&Co.IL现在持有538,410股这家生物技术公司的股票,价值2,563,000美元,上个季度又购买了2,925股。Kestra Consulting Services LLC在第一季度持有的免疫系统股票增加了14.6%。Kestra Consulting Services LLC现在拥有这家生物技术公司23,468股股票,价值11.2万美元,上个季度又购买了2,985股。最后,麦肯锡金融公司在第一季度增持了免疫基因公司4.4%的股份。麦肯锡金融公司(Mackenzie Financial Corp)目前持有这家生物技术公司80,816股股票,价值385,000美元,此前该公司在上个季度又购买了3,370股。机构投资者和对冲基金持有该公司95.58%的股票。
About ImmunoGen
关于免疫基因
(Get Rating)
(获取评级)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家临床阶段的生物技术公司,开发抗体-药物结合(ADC)疗法来治疗癌症。该公司的候选产品包括针对叶酸受体α(FRA)的ADC Mirvetuximab soravtansine,它正处于治疗对铂耐药的卵巢癌的第三阶段临床试验;以及Pivekimab Sunirine,一种针对CD123的ADC,正处于治疗急性髓系白血病和原始浆细胞样树突状细胞肿瘤的第二阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免费获取StockNews.com关于免疫基因的研究报告(IMGN)
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对免疫系统及相关公司评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧